Which hedge funds own TGTX? TG THERAPEUTICS INC, Q2 2026 13F holders
41 tracked hedge funds disclosed a position in TGTX (TG THERAPEUTICS INC) in their Q2 2026 13F filings, worth $860.4m in total. The largest holder by portfolio weight is Occam Crest Management LP at 12.5% of its book. 14 opened a new position this quarter: Exome Asset Management LLC, Semanteon Capital Management, LP, Weiss Asset Management LP, Fox Run Management, L.L.C.. 12 exited: Diadema Partners LP, Persistent Asset Partners Ltd, Braidwell LP.
- 41
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 14
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 12
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $67.5m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $26.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $860m
- Combined value Sum of the holders' reported positions in the security.
- 3.3%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Diadema Partners LP | 2.8% | $6.9m |
| Persistent Asset Partners Ltd | 0.7% | $1.8m |
| Braidwell LP | 0.4% | $11.9m |
| Twinbeech Capital LP | 0.09% | $910k |
| AlphaGrep UK Ltd | 0.09% | $308k |
| J. Goldman & Co LP | 0.07% | $1.6m |
| Bayforest Capital Ltd | 0.02% | $17.2k |
| SummitTX Capital, L.P. | 0.01% | $339k |
| Freestone Grove Partners LP | 0.01% | $810k |
| Y-Intercept (Hong Kong) Ltd | 0.01% | $304k |
| Magnetar Financial LLC | 0.0% | $419k |
| Hudson Bay Capital Management LP | 0.0% | $684k |
Ownership over time
Who discovered TGTX first? Beta
The run: Q2 2022 → Q2 2023, +484%
| 683 Capital Management, LLC | Q3 2021 | 1.0% | +6.6 pts |
| Paradigm Biocapital Advisors LP | Q2 2022 | 1.7% | +2.8 pts |
| Pura Vida Investments, LLC | Q3 2022 | 0.6% | +1.9 pts |
| Maverick Capital Ltd | Q3 2022 | 0.7% | +0.9 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.